JNJ

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✗

Return

+1.93%

Status

scored

Maintain JNJ at Hold with $247 hard stop and defined triggers. Bull trigger is $260 close with RSI >50 and volume ≥7.5M; bear trigger is $252.49 close (requires distribution confirmation, not low-volume sessions). Given 27-day political binary risk and confirmed bearish momentum, neither aggressive addition nor Underweight trim is warranted per the 10/05 and 10/06 binding lessons.

Outcome

✓

Return

-0.76%

Status

scored

Maintain JNJ in Hold with defined tactical triggers around the Oct 13 Q3 earnings binary event; trim 10-15% into any rally toward $264-270 (50 SMA resistance), keep $249 hard stop, and reserve 3-5% cash for a pre-committed buy at $240-245 on reversal candle with volume >7M. Q3 earnings serve as the binary reassessment trigger: beat-and-raise with ex-STELARA bridge ≥9% and constructive FY guide warrants reassessment to Overweight if $260+ reclaim holds, while miss or soft guide triggers the $249 stop and $240 structural floor preserves capital for re-entry.

Outcome

✗

Return

+1.44%

Status

scored

Maintain JNJ position at Hold; the 10/05 signal indicates mean-reversion long not breakdown short for this oversold defensive compounder, so do not add aggressively ahead of the Oct 13 Q3 catalyst with only 4-6 week tactical horizon, but preserve $235 stop and defined entry triggers at $240-245 flush or $265 breakout with volume/MACD confirmation; dividend reinvestment and AAA balance sheet structural floor provide long-term framework while awaiting the binary Q3 reassessment.

Outcome

–

Return

+0.73%

Status

scored

Maintain Underweight via protective put hedge rather than spot trim, as the hedge architecture resolves the tension between the binding 10/02 lesson (Hold is not neutral) and the binding 10/01 lesson (escalating trims amplify flawed directional views). Buy Dec 2026 $240-245 protective puts at ~1-1.5% of position notional to deliver convex downside protection on a 200 SMA break while preserving the core equity position; the ~3% dividend yield covers hedge cost, and post-Q3 binary resolution on Oct 13 will determine unwind or maintenance of the hedge.

Outcome

✗

Return

-1.21%

Status

scored

Maintain JNJ on hold with stop-loss trailing to $252; technical structure has broken (7.9% drawdown in 3 sessions, MACD crossover, all moving averages violated) but fundamental quality remains intact. Add only at $240-245 or on confirmed close above $260 with volume ≥7.5M, with Q3 earnings as the key binary catalyst in approximately 2 weeks.

Outcome

✓

Return

-1.02%

Status

scored

Trim JNJ by 30-40% from benchmark weight to Underweight following confirmed structural floor breakdown (50 SMA, 10 EMA, lower Bollinger lost in single session on 8.16M shares) and unjustified 21.3x forward P/E premium versus peers (MRK 13x, PFE 14x, ABBV 17x). The 9/30 binding reflection established that 25-30% trims failed to preserve alpha across three consecutive windows; 30-40% trim is required to neutralize asymmetric downside risk ahead of the Q3 earnings catalyst in 2-3 weeks while preserving the franchise-quality core for post-event reassessment.

Outcome

✓

Return

-2.30%

Status

scored

Trim 25-30% of JNJ into any rally at $268-270 over 1-2 weeks while maintaining 70-75% core exposure; do not add ahead of Q3 binary catalyst (mid-October). Hard stop at $258 daily close with re-engagement triggers at $253-255 pullback with momentum divergence or confirmed close above $280 on volume ≥10M with MACD positive cross.

Outcome

✗

Return

-1.06%

Status

scored

Maintain JNJ at current core weight without adding at $267 into the binary Q3 earnings catalyst (mid-October); if overweight versus benchmark, trim toward target on any retest of $270-272 to reduce variance exposure heading into the event. The structural thesis remains intact with AAA balance sheet and 64-year dividend streak, but the catalyst calendar—not valuation—is the binding constraint for the next 4-8 weeks.

Outcome

✗

Return

-1.61%

Status

scored

Maintain JNJ at 3–5% core portfolio weight collecting the ~2% dividend; do not add at current $271–272 levels. Hard stop at $263 daily close with volume (50 SMA + Bollinger lower band confluence) triggers 30–50% trim. Active HOLD with three-tier re-engagement ladder (Tier 1: $255–$260 pullback, Tier 2: $280 breakout on ≥20M volume, Tier 3: $237–$252 deep flush) and Q3 2026 earnings (mid-October) as the decisive catalyst for the 41% forward EPS expansion thesis.

Outcome

✓

Return

+0.27%

Status

scored

Maintain JNJ at 3-5% core portfolio weight collecting the ~2% dividend; do not add at current levels near $271. Hard stop triggers 50% trim at $264 daily close and full exit at $252; add only on breakout above $276 on volume ≥6M or pullback to $238-$252 zone with momentum divergence. Reassess at Q3 2026 earnings (mid-October) where the 41% forward EPS expansion thesis ($8.61 TTM → $12.14 forward) faces binary test via ex-STELARA bridge and Stelara erosion pace.

Outcome

✓

Return

+0.20%

Status

scored

Maintain JNJ at Hold with a $273 price target and 3-6 month tactical horizon, collecting the ~2% dividend while awaiting Q3 2026 earnings as the binary catalyst; the structural floor (50 SMA at $263, 200 SMA at $237, AAA credit, 64-year dividend streak) is intact but technical deterioration (negative MACD histogram, failed $281 breakout) argues against adding at current levels.

Outcome

✗

Return

+0.56%

Status

scored

Trim JNJ by 25–30% into the $268–$272 zone over 1–2 weeks to lock in part of the +58% TTM gain and reduce convexity into mid-October Q3 2026 earnings; maintain ~70% core exposure with a hard stop at $258 closing basis. The Underweight rating reflects consensus that multi-signal technical deterioration (MACD negative, RSI cooling toward 50, price below VWMA) warrants measured exposure reduction without abandoning the structural floor thesis (200 SMA at $237.19, AAA credit, 64-year dividend streak).

Outcome

✓

Return

-0.01%

Status

scored

Maintain JNJ core position at $269 with a two-tier entry framework: Tier 1 (50%) on confirmed close above $275 with positive MACD histogram cross, and Tier 2 (50%) on pullback to $260-265 with 50 SMA holding. Stop loss sits at $253 (volatility-adjusted at 1.5-2x ATR below entry), with Q3 earnings in mid-October as the decisive reassessment catalyst to resolve whether the embedded 41% forward EPS expansion materializes.

Outcome

✓

Return

-0.10%

Status

scored

Three-analyst convergence on Hold for JNJ at $269 reflects asymmetric risk-reward: approximately 6% upside to $285 versus approximately 11% downside to $239 on 50 SMA break, with unresolved debate on forward EPS expansion trajectory. Maintain 5-8% core weighting with no new exposure at current levels; add zones refined to $262-265 on confirmed 50 SMA defense with volume greater than 7M, and $276.88 breakout on volume greater than 7M with MACD re-cross. Q3 2026 earnings (mid-October) is the decisive reassessment catalyst for STELARA erosion cadence and ex-STELARA bridge validation.

Outcome

✓

Return

-0.19%

Status

scored

Three-way analyst unanimity on Underweight, with all three perspectives independently converging on trim execution in the $273-278 zone targeting ~70% benchmark weight, with stop discipline at $256-258. The catalyst cluster—particularly today's Trump healthcare-sector announcement with Polymarket pricing 100% probability of pharma language—creates genuine asymmetry: even benign-but-ambiguous headlines can produce a 2-3% air-pocket in crowded defensive rotation. The Underweight does not escalate to Sell given franchise quality (AAA balance sheet, $19.3B FCF, 62-year dividend streak) bounding downside; the 70% position preserves re-engagement optionality.

Outcome

✓

Return

-0.09%

Status

scored

Maintain JNJ at Hold with $270 unchanged price, as the structural floor (200 SMA at $236, AAA credit, 62-year dividend streak) remains intact and prior September trims already executed the required discipline. The neutral analyst's flexible add framework is adopted: accept scaled adds in the $262-268 zone on volume confirmation, with a $275 breakout trigger and $258 closing stop (1 ATR below 50 SMA).

Outcome

✓

Return

+1.10%

Status

scored

Analysts unanimously recommend HOLD for JNJ at ~$267 with a $262 stop-loss, rejecting both the aggressive analyst's spot-add call (MACD below signal, 30x trailing P/E) and the conservative's all-or-nothing $245-250 entry requirement. A three-tier technical entry framework is adopted: Tier 1 (25% capital) on close above $268 with positive MACD histogram, Tier 2 (25%) on reclaim $269.42 VWMA, and Tier 3 (50%) on pullback to $262-264 with 50 SMA holding—balancing catalyst upside capture against momentum risks. Key catalysts include Q3 earnings (mid-October) and the DePuy/Apollo deal close ($20B, 30-90 day window), with a 6-12 month tactical horizon and $275 price target.

Outcome

✓

Return

+0.03%

Status

scored

Maintain JNJ at $267.20 with a HOLD rating as all three analysts converge on the view that quality architecture (25.74% ROE, $22.2B FCF, 62-year dividend streak) and intact structural support at the 200 SMA ($235.53) justify holding against oscillator-only deterioration, with a $260 closing stop and 25-50% protective put overlay recommended through FOMC. Re-engagement triggers are defined: upgrade to Overweight on close above $281.07 on volume ≥7M with MACD histogram expanding above +1.0; conditional scale-in at $255-258 capitulation zone with RSI sub-40; reassess toward Underweight on weekly close below $261.76 (50 SMA) on volume >7M.

Outcome

✓

Return

+0.33%

Status

scored

Maintain JNJ at Hold rating with current price at $266.32, where all three analysts converge. The 9/09-9/11 Underweight sequence already executed the required 10-15% trim discipline, and adding another trim now would create the friction drag explicitly warned against in prior reflections. Three re-rating triggers define active engagement: upgrade to Overweight on breakout above $281.07 with volume ≥7M and MACD histogram expanding above +1.0; conditional scaling at $261 zone with RSI sub-40 and MACD histogram trough; or escalation to Underweight/Sell on weekly close below $255 on volume >7M.

Outcome

–

Return

+0.28%

Status

scored

Reduce JNJ exposure by 10-15% via a two-tranche phased trim: Tranche 1 (~5-7%) at-or-near market $266, with Tranche 2 (~5-8%) pre-staged as contingent sell orders at $269-273 to capture any relief bounce into the $275-280 resistance zone. The $259 mechanical stop is eliminated in favor of structural escalation logic; re-evaluation (not re-entry) triggers on close above $278 with MACD expansion and volume greater than 7M, while escalation toward Sell requires weekly close below $261.76 (50 SMA) on volume greater than 7M.

Outcome

✓

Return

-0.29%

Status

scored

Recommend a 10-15% phased reduction in JNJ with Tranche 1 (~5-7%) sold at or near market around $266 and Tranche 2 (~5-8%) pre-staged as contingent sell orders at $269-273 to capture any relief bounce. Re-entry requires both price discipline at the $240 and $234 structural floor zones and trend stabilization (50 SMA flattening/rising with positive MACD histogram). Full Sell is rejected as overreaction given JNJ's intact structural support—price sits 13.5% above the 200 SMA at $234.55 with AAA credit, a 62-year dividend streak, and 29.2% margins fully intact. Rating may escalate to Sell only on weekly close below $261.23 on volume >7M.

Outcome

–

Return

-0.27%

Status

scored

Analysts recommend reducing JNJ by 40-45% over 3-5 sessions near market prices (~$267 area) while preserving a 55-60% strategic core, based on synchronized technical breakdown including MACD crossing below signal, RSI collapsing from 65.95 to 50.99, and 9/08 distribution on 8.08M shares against a 6.5M average. The 31x TTM P/E and 4.38 PEG are cited as stretched valuations, while the AAA balance sheet, 60+ year dividend streak, and 25.7% ROE justify retaining a residual core position. Re-evaluation triggers are set at $281.50 (upgrade toward Hold) and $261.23 on closing basis with volume >7M (further trim toward Sell).

Outcome

✓

Return

-0.76%

Status

scored

Maintain JNJ as a Hold with a tactical trim of 7-10% of current holdings rather than a full Underweight or Hold-only approach, given the stock sits $8 above the 50 SMA at $261.04 with an intact long-term uptrend but faces compressed risk-reward at 99% of the 52-week high with a 31x trailing PE and 4.38 PEG ratio. Reframe the $281.07 level as a re-evaluation trigger (not an exit), with $261.04 as the structural escalation level for further trimming and $233.87 as the hard stop on a weekly close basis with volume >7M.

Outcome

✗

Return

-2.22%

Status

scored

JNJ is a HOLD at $275 based on asymmetric risk/reward (1.6% upside to $279.63 versus 5-7% downside to $260), a failed breakout at the upper Bollinger Band on 9/03, and stretched valuation (31.9x TTM P/E, 3.0-4.32x PEG). The core position should be maintained with the dividend collected, while stage limit-buy entries are set for pullbacks to $255-260 or confirmed breakouts above $279.63 on volume.

Outcome

✓

Return

-1.15%

Status

scored

Maintain HOLD on JNJ as the intellectually defensible rating given balanced bull/bear forces offsetting each other. New capital should not chase the $278 breakout—scale-in zones at $266-271, $250-260, and $235 deployed in thirds remain the disciplined approach. The structural hard stop stays at $233.10 (200 SMA); the aggressive analyst's proposed tightening to $240 is rejected as it would place the stop in the middle of the $258-262 consolidation zone and erode discipline through routine volatility triggers.

Outcome

✓

Return

+1.17%

Status

scored

Hold the full JNJ position as the 50 SMA floor at $258.72 remains intact with price $16 above it, MACD histogram turning positive, and three consecutive Underweight calls having produced positive alpha (8/27 +1.1%, 8/28 +2.3%, 8/31 +2.7%). The $281.07 intraday high rejection on 7.9M volume is consolidation, not distribution, with RSI at 64 constructive and the close remaining inside the prior consolidation range.

Outcome

✗

Return

+1.48%

Status

scored

JNJ is rated Hold with a $275 target over 6-12 months, as the AAA credit profile, $16.9B trailing free cash flow, and 60+ years of dividend growth support the existing position, but 22x forward P/E, a 4.66 PEG ratio, bearish RSI divergence, and $96.7B goodwill with negative tangible book make fresh entry unattractive at current $271-273 levels. The analyst recommends adding only in thirds toward $268, $263, and $258 with momentum confirmation, using $231.86 as the hard stop.

Outcome

✗

Return

+2.01%

Status

scored

Portfolio Manager rates JNJ UNDERWEIGHT and prescribes trimming 15-20% of the current position over 5-10 trading sessions at $262-263, while preserving an 80-85% core allocation to participate in any bullish resolution. Partial redeployment of trimmed capital into short-duration Treasuries (1-3 month bills) at 4.5% yield with the remainder in cash or defensive ETFs is recommended, with a structural stop at $256.28 on a closing basis.

Outcome

–

Return

-0.82%

Status

scored

Maintain Underweight rating on JNJ with a 10-15% position trim (reduced from the trader's proposed 25-40%), executed into the $268-272 zone on light-volume rejection, as the 21.78x forward P/E embedded 43% implied EPS growth ($8.61 TTM → $12.31 forward) creates unsustainable valuation risk given 4-5% organic growth and contracting Q2 EBITDA margins of 37.09% to 35.64%. Structural stop set at $263 (Bollinger middle) with mental stop at $255 (50 SMA), while proceeds should redeploy to cash or short-duration Treasuries yielding 4%+ rather than the rejected mid-cap biotech rotation thesis.

Outcome

✗

Return

+0.85%

Status

scored

Trim JNJ to ~80% of current weight over 10-15 trading sessions using rejected rallies at $268-272 as trim opportunities, executing around Jackson Hole rather than through it. The 50 SMA ($256.28) serves as the structural stop on a closing basis. Re-entry framework requires 10 EMA reclaim ($267.32) with ≥7M volume; preferred zone is $249-256, with full restoration only on $272 reclaim with expanding MACD histogram. Risk-reward shows ~4-6% upside to $275-285 versus 6% downside to $256.28 and 14-15% downside to $230.86.

Outcome

✗

Return

-1.57%

Status

scored

Analysts recommend holding JNJ at $270, avoiding both adding and trimming positions. The 17% extension above the 200 SMA, contracting momentum indicators (RSI divergence, MACD histogram contraction), and unresolved R&D contradiction (R&D fell 15% YoY while pipeline growth is the bull thesis) make adding indefensible. A tiered three-zone framework provides defined entry points at lower levels rather than chasing at current prices.

Outcome

✓

Return

-1.15%

Status

scored

Maintain JNJ at Hold given the empirical record (3 of last 5 Underweight calls wrong directionally), intact structural thesis (64-year dividend streak, 0.23 beta, ~$16.9B FCF, 25.7% ROE), and 86% no-cut probability favoring defensives—but avoid chasing after a 54% one-year rally at 4.73 PEG and 22x forward PE demanding 43% EPS growth. Execute staged trimming on confirmed breakout failure at $274.65 or failed bounce at 10 EMA (~$267), with structural stop at 50 SMA ($256) on a closing basis and covered calls at $280-285 to monetize the wait.

Outcome

✓

Return

+0.04%

Status

scored

Maintain JNJ core position at Hold; resist both the aggressive Buy and conservative Sell extremes despite valid individual points from each camp. The empirical record decisively rejects Underweight calls (3 of last 5 directionally wrong), yet the failed breakout attempts above $274.65 on soft 5.41M volume warrant execution discipline rather than directional capitulation. Trim a modest 10-15% only on confirmed breakout failure above $274.65 within three sessions or a pullback to the 10 EMA near $267 that fails to bounce, with stops tightened to the $261-263 zone on closing basis.

Outcome

✓

Return

+1.04%

Status

scored

Maintain JNJ at current weight with a Hold rating as the risk-reward is unfavorable for new capital at $270.01 (approximately 2% upside to 52-week high vs 8-10% downside risk to 50 SMA). Two entry triggers are defined: a pullback to $250-256 near the 50 SMA with RSI above 45 and no MACD bearish crossover, or a confirmed breakout above $273.38 with volume exceeding 7.5M shares. Trailing stop anchored at $254.83 on a closing basis.

Outcome

✓

Return

+1.07%

Status

scored

Maintain JNJ at core weight without chasing at $267, as the 21.7x forward P/E with contracting EBITDA margins (37.09% → 35.64%) offers poor risk/reward for new capital; scale new entries via a tiered approach at $258, $261.80 (20 SMA), and $254 (50 SMA retest) if reached, while tightening the stop to structural $250 and trimming 15-20% only on confirmed closes above $272 with volume exceeding 7M.

Outcome

✗

Return

-2.21%

Status

scored

JNJ is rated HOLD with a $275 price target over 6–12 months; existing positions should be maintained but no new capital added at the current $273.41 level due to elevated 22.2x forward P/E, 4.56x PEG ratio, overbought RSI of 68.59, and breakout volume of only 6.26M shares falling short of the 7M confirmation threshold. New exposure of 2–3% maximum should be deployed in 1–1.5% tranches on a supported $261–264 pullback or 1% on a close above $276.47 with at least 7M shares; tactical reassessment triggers below $253.59 50 SMA, with $227 as the hard structural stop.

Outcome

✓

Return

+0.85%

Status

scored

Maintain JNJ exposure at $271 as the empirical track record (3 of last 5 Underweight calls wrong) and structural defensive moat (0.23 beta, 64-year dividend streak, $19B annual FCF) argue against crystallizing gains; do not add into the one-day breakout and do not trim into strength. Position sizing is tiered: first tranche add on pullback to 10 EMA (~$262) with volume, second tranche on confirmed close above $280 with volume >7M.

Outcome

✗

Return

+3.33%

Status

scored

Underweight JNJ with a 20-25% trim recommended at $260-266, reducing exposure to a 21.3x forward P/E and 4.56 PEG ratio that price in ~43% EPS growth the 6.6% revenue trajectory cannot support; preserve 75-80% core position to retain defensive characteristics (0.23 beta, AAA credit, 64-year dividend streak) while redeploying proceeds 50/50 into intermediate Treasuries (3-5yr) and cash buffer to capture 200+ bps yield pickup over the 2.06% dividend yield. Re-engagement is conditional and mechanical—tight stop at $247 on remaining position, hard stop at $228.

Outcome

✗

Return

+0.78%

Status

scored

Trim JNJ by 20-25% at $260-265 given unfavorable risk/reward (6% upside to $275 vs. 12% downside to $228), valuation premium at 21.2x forward P/E, and dividend yield of 2.05% that underperforms the risk-free rate; set stop at $247 on remaining 75-80% and redeploy proceeds into short-duration Treasuries yielding 4-4.5%.

Outcome

✓

Return

-0.66%

Status

scored

Portfolio Manager maintains Underweight (SELL) rating on JNJ with a 20-25% trim recommended at $260-265, redeploying proceeds into 50% cash and 50% short-duration Treasuries for a 4-4.5% yield pickup. The position reduces benchmark weight given the 30.4x trailing P/E valuation premium, 2.06% dividend yield below the risk-free rate, and absence of near-term catalysts, while preserving 75-80% of the position with stops at $247 tight and $240 hard.

Outcome

✓

Return

+0.47%

Status

scored

Maintain JNJ at Hold; new money should await a pullback to the $249-$256 zone rather than adding at current $260.86, with stops placed at $244-$245 (1.5 ATR below entry, not the flawed $249 level that conflates entry and stop). Overweight positions should defer trimming to $265-$268 until a confirmed rejection at $268 forms, avoiding premature carry crystallization. Hard invalidation triggers below $249; bullish confirmation requires a daily close above $268.50 on >8M volume with RSI >65.

Outcome

–

Return

+0.41%

Status

scored

Trim JNJ toward neutral or below-benchmark weight using a tiered 1/3 approach—sell first tranche near $266 on declining volume, second on close below $258.76 (10 EMA), and reserve final tranche for breakdown below $254 or stop-loss at $274.90; re-entry zones at $230-240 (200 SMA/PEG ~3.0-3.2x) or below $249 (50 SMA) on expanding volume.

Outcome

✓

Return

-0.77%

Status

scored

Maintain JNJ core position at $262 without adding or trimming, as the $5.5B talc settlement and OTTAVA FDA authorization catalysts are largely priced into the 21.3x forward P/E. Technicals (MACD rollover, 5.87M vs 8-10M volume needed) argue against chasing at resistance $268-269, while the structural thesis (64-year dividend growth, diversified pipeline) argues against selling. Execute a two-trigger framework: add on bullish breakout (daily close >$268.26 on >8M volume) targeting $278-285, or trim on bearish breakdown (daily close <$250.91 with expanding volume/MACD re-cross), with stop at $226.85 (200-SMA). Upside to $270 target is +6.2% at 12-18 month horizon versus downside to 200-SMA of -13.4%.

Outcome

✓

Return

+0.99%

Status

scored

Maintain JNJ as a HOLD with a 12-18 month horizon, as the structural bull case is substantially priced in after the 60% rally and the technical setup shows unambiguous momentum deterioration (MACD bearish cross, RSI cooling, ATR +40%). Entry is disciplined: 2-3% add on 50 SMA retest at $247.73 with RSI > 45, scaling to 5% on 200 SMA test at $226.49 with MACD confirmation, with a stop below $245 invalidating the constructive setup and fair value near $270.